Monday, 9 Jun 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • White
  • VIDEO
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Colossal
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
Economy

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Last updated: April 23, 2025 6:12 pm
Share
Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
SHARE

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that has been in the spotlight recently as one of the cheap NASDAQ stocks to buy according to hedge funds. With a forward P/E ratio of 13.24 and 74 hedge fund holders, Gilead is making waves in the industry.

In a recent interview on CNBC, Dan Ives, Head of Global Tech Research at Wedbush Securities, discussed the current state of the tech sector, highlighting the potential for major volatility ahead. The uncertainty in the tech industry has been exacerbated by escalating tariffs on China, reaching as high as 125%. This has forced companies to rethink their supply chains and has resulted in a noticeable pause in tech spending.

Despite the challenges, Ives has not downgraded tech stocks, emphasizing the potential for clear winners to emerge from the current turmoil. He predicts that Street estimates are likely to see earnings cuts of about 10% across internet and big tech companies, reflecting the broader pullback in spending and ongoing volatility.

Gilead Sciences has seen success in its HIV franchise, with sales reaching $19.6 billion in 2024. Key products like Biktarvy and Descovy have contributed to this growth, solidifying Gilead’s position in the market. While the company expects some temporary challenges in 2025 due to Medicare Part D reform, the underlying HIV business remains strong.

In a recent investor letter, ClearBridge Value Strategy praised Gilead’s performance, citing strong fourth-quarter earnings growth and positive reception to its new treatments. Overall, Gilead ranks 9th on the list of cheap NASDAQ stocks to buy according to hedge funds.

See also  Global stock markets tumble as Donald Trump’s tariffs loom

While Gilead shows promise, there are other opportunities in the market, particularly in AI stocks. These stocks have the potential to deliver high returns in a shorter time frame. If you’re looking for an AI stock with significant growth potential, consider exploring the cheapest AI stock highlighted in our report.

In conclusion, Gilead Sciences is positioned as a strong contender in the biopharmaceutical industry, with a solid track record and promising future prospects. However, investors should also consider exploring opportunities in AI stocks for potentially higher returns. Stay informed and make informed investment decisions based on the latest market trends and opportunities.

TAGGED:BuyCheapfundsGILDGileadhedgeNasdaqSciencesStock
Share This Article
Twitter Email Copy Link Print
Previous Article Can climate science attribute economic damage to major polluters? Can climate science attribute economic damage to major polluters?
Next Article How Legal Aid’s pro-crime push puts all of us in danger How Legal Aid’s pro-crime push puts all of us in danger
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

See Meghan Trainor’s Sexiest Photos After Weight-Loss Transformation

Trainor made a stunning appearance at Billboard's 2025 Women in Music Awards, turning heads in…

May 29, 2025

Where to watch Arsenal vs. Tottenham: Live stream Premier League, start time, TV channel, odds, pick

The highly anticipated north London derby between Arsenal and Tottenham is set to take place…

January 14, 2025

September 25, Bill Cosby sentenced in sexual assault case

Today is Wednesday, September 25, 2024, marking the 269th day of the year with 97…

September 25, 2024

The Eagles defense couldn’t stop Mahomes in 2022. In Super Bowl 59 they got their revenge

The Philadelphia Eagles pulled off a stunning victory in Super Bowl LIX, dismantling the Kansas…

February 10, 2025

Curbing plastics pollution could help reduce global burden of breast cancer, analysis suggests

Plastic pollution has become a major concern globally, not only for its impact on the…

December 2, 2024

You Might Also Like

EU to ‘step up’ on cyber security as dependence on US laid bare
Economy

EU to ‘step up’ on cyber security as dependence on US laid bare

June 9, 2025
Qualcomm strengthens AI portfolio with .4 billion Alphawave deal
Economy

Qualcomm strengthens AI portfolio with $2.4 billion Alphawave deal

June 9, 2025
The demise of the penny?
Economy

The demise of the penny?

June 9, 2025
Military veterans object to Donald Trump’s intervention in Los Angeles
Economy

Military veterans object to Donald Trump’s intervention in Los Angeles

June 9, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?